Evidence of Drug-Drug Interactions through Uptake and Efflux Transport Systems in Rat Hepatocytes: Implications for Cellular Concentrations of Competing Drugs

Drug Metabolism and Disposition

Volumn 41, Issue 8, 2013, Pages 1548-1556

  Daali, Youssef ^a   Millet, Philippe ^b   Dayer, Pierre ^a   Pastor, Catherine M ^b,c  

^a Service de Pharmacologie et Toxicologie Cliniques   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; RIFAMPICIN;

ANIMAL TISSUE; ARTICLE; CELL LEVEL; CELL TRANSPORT; DRUG CONCENTRATION; DRUG INTERACTION; DRUG TRANSPORT; DRUG UPTAKE; LIVER CELL; MALE; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HEPATOCYTES; MALE; MEGLUMINE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANOMETALLIC COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN;

EID: 84880665181     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.051870     Document Type: Article

References (54)

1. Acocella G (1983) Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 5 (Suppl 3):S428-S432.
2. Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631-1643.
3. Crawford JM, Berken CA, and Gollan JL (1988) Role of the hepatocyte microtubular system in the excretion of bile salts and biliary lipid: implications for intracellular vesicular transport. J Lipid Res 29:144-156.
4. de Haën C, La Ferla R, and Maggioni F (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. J Comput Assist Tomogr 23 (Suppl 1):S169-S179.
5. Fahrmayr C, Fromm MF, and König J (2010) Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42:380-401.
6. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
7. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
8. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
9. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55: 4740-4763.
10. Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, and Weinmann HJ (2002) Gadoliniumethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680-684.
11. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handbook Exp Pharmacol 201:299-323.
12. Kindla J, Fromm MF, and König J (2009) In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 5:489-500.
13. Köck K and Brouwer KL (2012) A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 92:599-612.
14. Kusuhara H and Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
15. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) Effects of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81: 194-204.
16. Lehmann GL, Larocca MC, Soria LR, and Marinelli RA (2008) Aquaporins: their role in cholestatic liver disease. World J Gastroenterol 14:7059-7067.
17. Li L, Meier PJ, and Ballatori N (2000) Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 58:335-340.
18. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, and Grundström R, et al. (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129:476-485.
19. Millet P, Moulin M, Stieger B, Daali Y, and Pastor CM (2011) How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver. J Pharmacol Exp Ther 336:624-632.
20. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, and Sugiyama Y (2006) Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
21. Mottino AD, Carreras FI, Gradilone SA, Marinelli RA, and Vore M (2006) Canalicular membrane localization of hepatocyte aquaporin-8 is preserved in estradiol-17beta-D-glucuronide-induced cholestasis. J Hepatol 44:232-233.
22. Nakanishi T and Tamai I (2012) Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 27: 106-121.
23. Nassif A, Jia J, Keiser M, Oswald S, Modess C, Nagel S, Weitschies W, Hosten N, Siegmund W, and Kühn JP (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741-750.
24. Neyt S, Huisman MT, Vanhove C, De Man H, Vliegen M, Moerman L, Dumolyn C, Mannens G, and De Vos F (2013) In vivo visualization and quantification of (disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTc-mebrofenin in mice. J Nucl Med 54:624-630.
25. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
26. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, and Inui K (2010) Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 25:190-199.
27. Oh ES, Kim CO, Cho SK, Park MS, and Chung JY (2012) Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet DOI: 10.2133/dmpk.DMPK-12-RG-068.
28. Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, and Vallée J-P (2003) Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 229:119-125.
29. Pastor CM, Williams D, Yoneyama T, Hatakeyama K, Singleton S, Naylor E, and Billiar TR (1996) Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver. J Biol Chem 271:24534-24538.
30. Pastor CM, Wissmeyer M, and Millet P (2013) Concentrations of Gd-BOPTA in cholestatic fatty rat livers: role of transport functions through membrane proteins. Contrast Media Mol Imaging 8:147-156.
31. Planchamp C, Beyer GJ, Slosman DO, Terrier F, and Pastor CM (2005a) Direct evidence of the temperature dependence of Gd-BOPTA transport in the intact rat liver. Appl Radiat Isot 62: 943-949.
32. Planchamp C, Hadengue A, Stieger B, Bourquin J, Vonlaufen A, Frossard J-L, Quadri R, Becker CD, and Pastor CM (2007) Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol Pharmacol 71: 1089-1097.
33. Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, and Gex-Fabry M (2005b) Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Invest Radiol 40:705-714.
34. Rodrigues AC (2010) Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 6:621-632.
35. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
36. Shitara Y (2011) Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet 26:220-227.
37. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
38. Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, Lechat P, Leblond V, and Hulot JS (2012) Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J DOI: 10.1038/tpj.2012.37.
39. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug-and estrogeninduced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
40. Takashima T, Hashizume Y, Katayama Y, Murai M, Wada Y, Maeda K, Sugiyama Y, and Watanabe Y (2011) The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [11C]telmisartan. Mol Pharm 8: 1789-1798.
41. Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, Ijuin R, Shiomi S, Nakae T, and Watanabe Y, et al. (2012) PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J Nucl Med 53:741-748.
42. Tietz P, Jefferson J, Pagano R, and Larusso NF (2005) Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J Lipid Res 46: 1426-1432.
43. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
44. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, and Dekhuijzen R (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192-202.
45. Van Beers BE, Pastor CM, and Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421-429.
46. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH (2010) Organic anion transporting polypeptide 1a/1bknockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942-2952.
47. Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, and Kullak-Ublick GA (2004) The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 40:212-218.
48. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
49. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
50. Watanabe T, Kusuhara H, and Sugiyama Y (2010) Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 37:575-590.
51. Yoshida K, Maeda K, and Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581-612.
52. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, and Borst P (2003) Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 278:23538-23544.
53. Zhang L, Zhang Y, and Huang SM (2009) Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm 6:1766-1774.
54. Zheng HX, Huang Y, Frassetto LA, and Benet LZ (2009) Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78-85.